Both Indiana University and Memorial Sloan Kettering Cancer Center (MSKCC) have published their series’ of salvage high-dose chemotherapy, Indiana using the carboplatin + etoposide regimen and MSKCC ...

Improved progression-free survival in metastatic urothelial carcinoma was observed in patients experiencing neuropathy, skin rash, and hyperglycemia following enfortumab vedotin.

Background: Neuroendocrine ... Diagnosis confirmed by pathology (4). Patients aged 18-45 years at diagnosis (5). Complete clinical data and follow-up information. Exclusion criteria (1): Patients with ...

Cancer Prevention Research publishes articles that focus on cancer prevention, preclinical, clinical, and translational research, with special attention given to molecular discoveries and an emphasis ...

Subepithelial lesions (SLEs) are often detected incidentally during endoscopic examination. They represent a heterogeneous ...

Early prostate cancer usually causes no symptoms, but can include blood in the urine or semen. The outlook is often excellent, especially if doctors diagnose it in the early stages. Prostate ...

2Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, Washington. 3Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington. 1Division of Human ...

It is still useful to provide pretesting likelihoods, but models need to take into account tumour pathology. Methods The Manchester Scoring System (MSS) is a well-used, simple, paper-based model for ...

Background: Follicular thyroid cancer (FTC) is the second most common malignancy of thyroid. About 7%–23% of patients with FTC have distant metastasis. The aim of this study was to investigate the ...

Understanding tumour heterogeneity is critical when developing novel treatment strategies. However, a comprehensive investigation of tumour heterogeneity in HCC is lacking, and the available evidence ...

This combination has “the potential to become a new standard first-line treatment” for well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors with poor prognostic factors ...